Background. The optimal penetration of antiretroviral agents into the central nervous system may be a balance between providing adequate drug exposure to inhibit human immunodeficiency virus (HIV) replication while avoiding concentrations associated with neuronal toxicities.
may be associated with improved clinical outcomes, such as cognitive function [3] . Conversely, greater penetration of antiretroviral agents may be associated with an increased propensity for drug-related CNS toxicities [4] .
The use of antiretroviral agents at doses lower than those currently licensed may offer several benefits including reduced healthcare costs and the potential to reduce drug-associated toxicities. Recently, an antiretroviral regimen containing efavirenz (EFV) dosed at 400 mg once daily rather than the currently approved dose of 600 mg once daily has shown virological noninferiority within a randomized controlled study [5] . The CNS exposure of EFV at this lower dose has not previously been determined.
EFV is metabolized by the cytochrome P450 (CYP) isoenzyme to several products, including 8-hydroxy efavirenz (8OH-EFV), the major metabolite via CYP2B6 [6] , and, to a lesser extent, to 7-hydroxy efavirenz (7OH-EFV) via CYP2A6 [7] . Although these metabolites are reported to be inactive in terms of antiviral activity [8] , they may be associated with toxicities. Potential CNS toxicities are reported to be associated with 8OH-EFV [9] .
The aim of this study was to assess the cerebrospinal fluid (CSF) exposure, as a surrogate for CNS exposure, of EFV and its major metabolites when dosed at 400 mg and 600 mg once daily in HIV-infected subjects after at least 12 weeks of commencing initial antiretroviral therapy. Furthermore, we assessed the number of subjects with EFV CSF exposure above concentrations expected to be associated with virological efficacy [10] , and 8OH-EFV CSF exposure above concentrations potentially associated with neuronal toxicity [9] .
METHODS

Subject Selection
Antiretroviral-naive, HIV-infected adults entering the ENCORE1 study (A randomized, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced-dose EFV with standard-dose EFV plus tenofovir and emtricitabine in antiretroviral-naive HIV-infected individuals over 96 weeks; see http://clinicaltrials.gov/ct2/show/NCT01011413 [5] ) were eligible to enter this substudy at 5 participating clinical sites (St Mary's Hospital and Chelsea and Westminster Hospital, London, United Kingdom; Medical Group Practice, Berlin, Germany; and Thai Red Cross AIDS Research Centre, Bangkok, and Khon Kaen University Hospital, Khon Kaen, Thailand). Additional exclusion criteria to the parent study included active CNS opportunistic infections or contraindications to CSF examination.
Local human ethics committee approval was granted prior to recruiting participants at each individual study site. All patients were required to sign an informed consent prior to commencing study screening procedures.
Study Procedures
Between 12 and 24 weeks of commencing study therapy, CSF examination was undertaken at least 8 hours after dosing of study medication. General safety assessments, including cerebral imaging and assessment of blood clotting, were undertaken as per usual clinical practice at each site prior to undertaking a lumbar puncture examination. The following analyses on CSF samples were undertaken: total protein; assessment of EFV, 8OH-EFV, and 7OH-EFV; and CSF HIV RNA level.
Blood sampling immediately prior to CSF examination was undertaken to assess plasma EFV, 8OH-EFV, and 7OH-EFV concentrations.
Pharmacokinetic, Pharmacogenomic, and Ultrasensitive HIV RNA Analysis
Concentrations of total (conjugated and unconjugated to plasma proteins) EFV and its metabolites in plasma and CSF were analyzed by high-performance liquid chromatography-tandem mass spectrometry by methods previously described [11] . In brief, freshly prepared standards and quality control samples ( prepared in artificial CSF) and clinical samples (100 µL) were incubated at 37°C for 2 hours with 400 µL of a solution containing 200 units of β-glucuronidase from Helix pomatia in 0.2 M sodium acetate buffer ( pH = 5). An internal standard (hexobarbital) was added and samples were subsequently alkalinized with 20 µL of potassium carbonate buffer (0.1 M, pH = 9.4) and then extracted with 3 mL of ethylacetate:hexane (60:40 v/v). After centrifugation, the organic phase was evaporated to dryness and the residue reconstituted in 100 µL of mobile phase (50/50 v/v acetonitrile [ACN]/water [H 2 O] in 1 mM ammonium acetate). Quantification was performed using a Thermo Vantage Triple Quadrupole mass spectrometer using selective reaction monitoring in negative ionization mode.
The lower limit of quantification (LLOQ) for plasma EFV, 8OH-EFV, and 7OH-EFV and CSF EFV, 8OH-EFV, and 7OH-EFV was 25, 5, 5, 2.5, 1.25, and 0.625 ng/mL, respectively. Interand intra-assay precision did not exceed 10% for any compound. The CYP2B6 516G→T genetic polymorphism was identified by real-time polymerase chain reaction (PCR) [12, 13] .
Quantification of CSF HIV RNA was performed using a highly sensitivity in-house assay with a detection limit of 2 RNA copies/mL, assuming an available volume of 2 mL. When <2 mL sample was available, the cutoff was adjusted proportionately. In brief, virus was pelleted by centrifugation and RNA extracted by the Qiagen MinElute method. The eluate was reverse-transcribed and amplified for 20 cycles using the Invitrogen One-Step method, and PCR products were quantified in a nested real-time PCR using the Qiagen Probe PCR method. A standard curve was generated from dilutions of the international working reagent WR1 (National Institute for Biological Standards and Control, Potters Bar, UK) [14] .
Statistical Analyses
Subject characteristics and laboratory parameters were analyzed descriptively. Geometric means and 90% confidence intervals (CIs) were calculated for EFV, 8OH-EFV, and 7OH-EFV exposure in both the plasma and CSF compartments for both randomized treatment groups (EFV dosed at 400 and 600 mg). Interpatient variability in these pharmacokinetic parameters was expressed as a coefficient of variation [(standard deviation/mean) × 100]). The number of subjects with CSF EFV concentrations >0.51 ng/mL (the postulated CSF 50% maximal inhibitory concentration [IC 50 ] for wild-type virus [10] ) and CSF 8OH-EFV concentrations >3.3 ng/mL (a concentration associated with neuronal toxicity in a laboratory model [9] ) were assessed for both randomized treatment arms.
In an exploratory analysis, associations between CSF 8OH-EFV exposure and Depression Anxiety Stress Scales [15] , an EFV symptom questionnaire (ESQ) [16] , and functional health status (12-item short-form) scores [17] at week 48 were assessed. The ESQ is designed to specifically elucidate responses from subjects on experiences over the past week that may be associated with EFV use such as vivid dreams, being off balance, restless sleep, and hangover-type drowsiness.
RESULTS
Subject Characteristics
Baseline characteristics are summarized in Table 1 . Race/ethnicity was similar in both study treatment groups (9, 5, and 1 [400-mg group] and 11, 4, and 1 [600-mg group] subjects of Asian, white, and African race/ethnicity, respectively). Successful CSF examination was achieved in 28 subjects. Lumbar puncture examination was unsuccessful in 1 subject allocated to 400 mg of EFV and 2 subjects allocated to 600 mg of EFV after 2 attempts. Further attempts were not considered clinically appropriate. Lumbar puncture examination was performed after a mean of 22 weeks (range, 11-25 weeks) after commencing study therapy, at which time all subjects remained on randomized study therapy.
Mean CSF protein was 0.40 g/dL (range, 0.24-1.02 g/dL). At the time of the CSF examination, plasma HIV RNA was undetectable in all subjects (<5 copies/mL in all but 1 subject in whom HIV RNA was <10 copies/mL due to a small volume for analysis), and CSF HIV RNA was also undetectable in all subjects (again <5 copies/mL in all but 1 subject, due to CSF volume constraints, the cutoff was 10 copies/mL).
Pharmacokinetic Results
Exposure of EFV and its major metabolites in the plasma and CSF are shown in Table 2 . Concentrations of EFV in both the plasma and CSF were slightly lower when dosed at 400 mg vs 600 mg, although this was not statistically significant (geometric mean ratio [GMR], 0.76 [90% CI, .53-1.09] and 0.84 [90% CI, .61-1.18] for plasma and CSF, respectively). There were no significant differences in overall CSF to plasma ratio for EFV concentration between the 2 study doses, and CSF EFV concentration was not associated with CSF protein (P = .60, Spearman correlation).
A similar trend was observed for 7OH-EFV exposure between the 2 studied doses of EFV. Concentrations of 7OH-EFV in the CSF were below the assay LLOQ of 0.625 ng/mL in 15 subjects (7 and 8 on EFV 400 mg and 600 mg, respectively).
A different trend was observed regarding 8OH-EFV exposure ( Figure 1 and Table 2 ). Plasma exposure of 8OH-EFV was similar when EFV was dosed at 400 mg vs 600 mg (GMR, 1.04 [90% CI, .76-1.43]), and CSF exposure followed a similar pattern, with exposure slightly increased in the 400-mg arm (GMR [400 mg/600 mg], 1.65 [90% CI, 1.09-2.50]). When excluding 1 outlier with a high CSF 8OH-EFV concentration (13 ng/mL), this observation persisted (GMR [400 mg/600 mg], 1.53 [90% CI, 1.01-2.32]).
Concentration of EFV in CSF at 8-16 hours postdose was >0.51 ng/mL in all subjects in both treatment groups, and exposure of 8OH-EFV in the CSF was >3.3 ng/mL in 11 of 14 and 7 of 14 subjects allocated to the 400 mg and 600 mg doses of EFV, respectively (P = .095 for differences between randomized treatment groups).
Factors Associated With CSF 8OH-Efavirenz Exposure
As we observed a trend toward higher exposure of 8OH-EFV in the CSF with the lower dose of EFV studied, we undertook exploratory analyses to assess pharmacokinetic and clinical factors associated with the exposure of this metabolite. Although CSF EFV exposure was associated with plasma EFV exposure (Spearman correlation coefficient 0.70, P < .001), CSF 8OH-EFV exposure was not significantly associated with either plasma EFV or plasma 8OH-EFV exposure (Spearman correlation coefficient −2.3 and 0.08, P = .242 and .674, respectively). Pharmacogenomic associations between CSF EFV and its metabolites are shown in Table 3 . As expected, higher CSF EFV exposure was observed in subjects with GT or TT genotypes in CYP2B6. However, no association was observed between CSF 8OH-EFV concentration and the CYP2B6 genotypes tested. Interestingly, the ratio of CSF 8OH-EFV to CSF EFV exposure was lower in subjects with GT or TT genotypes in CYP2B6; this effect was not observed for the ratio of CSF 7OH-EFV to CSF EFV.
Exposure of CSF 8OH-EFV was significantly associated with a variety of patient reported outcomes from the main EN-CORE1 study including ESQ results at weeks 4 and 48 (Table 4 ).
DISCUSSION
We have made several interesting observations when assessing the CSF exposure of EFV and its major metabolites in virologically suppressed adult patients dosed at 400 mg and 600 mg once daily. As expected, the CSF exposure of EFV was slightly lower when EFV was dosed at 400 mg vs 600 mg daily. However, CSF exposure of the 8OH-EFV metabolite was similar with both dosing schedules, with a trend toward higher concentrations observed with the 400-mg dosing schedule. Concentrations of EFV in CSF remained above 0.51 ng/mL, a postulated CSF IC 50 for wild-type virus [10] , for all subjects with both dosing schedules. EFV-containing antiretroviral regimens have been associated with several clinical CNS toxicities including neuropsychiatric effects [16] , cognitive deficits [18] , and suicidal ideation [19] . The pathogenesis of these toxicities is unknown, with several mechanisms proposed. One proposed mechanism, which has been studied in laboratory models, is a direct neurotoxicity from EFV and its metabolites [9, 20, 21] . Such laboratory models have reported the 8OH-metabolite of EFV to have a greater propensity for neuronal toxicities compared to the parent compound and other metabolites. Potential toxic effects include alterations of astrocytic glucose metabolism [20] , dendritic spine injury to neuronal cell lines [9] , and the production of toxic quinone-imine derivatives during oxidative degradation [21] .
Translating laboratory models into clinical practice is challenging; however, it is of interest to know if the 8OH-EFV concentrations we have observed in this clinical cohort are within the concentration ranges studied in laboratory models. Based on the model by Tovar-y-Romo et al [9] , the CSF concentrations of 8OH-EFV we have observed were above suggested toxic thresholds in 11 of 14 and 7 of 14 subjects allocated to the 400-mg and 600-mg dosing schedules, respectively. Furthermore, we did observe associations between CSF 8OH-EFV exposure and patient-reported CNS toxicities, with these toxicities being the frequent clinical side effects reported with EFV use, giving credence to the translation of such laboratory models into a clinical perspective. These findings are, however, limited by the post hoc nature of this analysis, the small number of subjects included, and the predominantly male Asian and white subjects recruited.
The pharmacogenomic results we have observed may provide plausible explanations for some of our pharmacokinetic findings. As expected, we observed an association between CSF and plasma EFV exposure; also, as expected, higher CSF EFV exposure was observed in subjects with GT or TT genotypes in CYP2B6. Therefore, in subjects with a slower EFV metabolism genotype, plasma exposure of EFV is higher compared to those with faster EFV metabolism genotype and, as expected, CSF exposure is also higher.
However, such a signal was not observed for CSF 8OH-EFV exposure, where CSF concentrations were similar between subjects with GG and in those with GT or TT genotypes in CYP2B6. Also, the ratio of CSF 8OH-EFV to CSF EFV exposure was statistically significantly lower in subjects with GT or TT genotypes, but this effect was not observed with the 7OH-EFV metabolite. We postulate that the underlying pharmacokinetic processes associated with CSF 8OH-EFV exposure may be subject to a saturation effect whereby exposure to this metabolite is not dependent on plasma EFV exposure or CYP2B6 genotype (both of which we have observed), but is rather a spillover from plasma 8OH-EFV or local CNS production of 8OH-EFV whereby this metabolite becomes "trapped" within the CNS compartment. A possible saturable process may be glucuronidation of 8OH-EFV in the CNS compartment whereby this saturated compound is unable to cross the blood-brain barrier; within the different EFV dosing schedules studied in our trial, the exposure of the 8OH-EFV metabolite in the CSF was independent of EFV dose, plasma exposure, and CYP2B6 genotype. A further explanation for our findings could be secondary to the effects EFV has on CYP2B6 induction. EFV is extensively metabolized by the CYP2B6 isoenzyme group, mainly to the 8OH-EFV metabolite, and is also an autoinducer of its own metabolism via induction of CYP2B6 [22] . The CYP2B6 isoenzymes are present not only in hepatic tissue but also in the blood-brain barrier [23] , raising the possibility for local EFV metabolism within the CNS compartment. If EFV autoinduction was dose proportionate, then with higher doses of EFV and greater autoinduction, greater concentrations of the 8OH metabolite would be expected. However this is not in keeping with our observations. Conversely, if the effects of EFV on autoinduction are not dose proportionate, and could even be greater with lower doses or vary in anatomical locations with varying doses, increased induction of CYP2B6 could lead to increased concentrations of metabolites produced via this pathway, such as the 8OH-EFV metabolite, even when a lower dose of the parent drug is administered. However, one would expect an autoinduction effect for a specific dose of a drug to be similar between subjects with faster and slower metabolism genotypes; we did not observe this effect in our study and therefore do not think a differing effect on autoinduction is a plausible explanation for our findings.
Antiretroviral drug delivery to the CNS is dependent on several influx and efflux transport proteins expressed at the bloodbrain barrier. Changes in the expression of these transporters may alter the exposure of antiretroviral drugs in the CNS, and antiretroviral agents including EFV and metabolites of EFV may themselves alter expression of such transporters [24] . Such effects, if present, may vary with EFV dose. It is possible that with higher doses of EFV, greater expression of efflux transport proteins may occur. An upregulation in efflux transporters that was dependent on EFV dose and particularly affected the removal of 8OH-EFV from the CNS provides another theoretical explanation for our findings.
Within the main ENCORE1 study, no differences in the number of patients reporting adverse events were observed, although study drug-related adverse events were more frequently observed in the 600-mg group than in the 400-mg group [5] . These study drug-related adverse events occurred predominantly early, within the first 12 weeks of the study. We believe our study provides one possible explanation for these findings, whereby the lack of difference in overall patient reported adverse events may be related to the lack of difference in 8OH-EFV exposure in both the plasma and CSF compartments with the different doses of EFV studied.
The ideal dose of EFV may be one that, on the one hand, maintains adequate plasma and sanctuary site exposure to induce and maintain an effective virological response, yet also limits exposure in sanctuary sites, including the CNS, to concentrations below those associated with toxicity. Our study suggests that although 400 mg of EFV is associated with CSF exposure of EFV above the concentration required to suppress HIV replication, exposure of metabolites may still be within the concentration range associated with toxicities.
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